Blueprint

Blueprint has converted the most-watched personal longevity experiment on earth into a fast-growing consumer brand. Bryan Johnson's regimen — publicly documented, obsessively quantified, and amplified by a Netflix documentary and a "Don't Die" movement — is a marketing engine no supplement competitor can buy, and Blueprint monetizes that attention through precision-dosed, third-party-tested products spanning the flagship Longevity Mix, functional foods and oils, at-home biomarker tests, and a Don't Die app. The October 2025 raise of roughly $60M from a star-studded roster of around 50 individual investors (reportedly including Kim Kardashian, Naval Ravikant, and the Winklevoss twins), at a reported ~$250M valuation, validated the brand's pull, and the company has professionalized: co-founder Kate Tolo turned Johnson's self-experiment into a public science project, and former Modern Health president Gyre Renwick took the CEO seat in 2025 so Johnson could focus on vision and protocol. The strategy is a coherent "measure, then optimize" ecosystem rather than a single SKU, letting customers buy into pieces of the protocol at a range of price points — from $333/month subscriptions to the $1M/year "Immortals" concierge tier launched in early 2026. If biohacking becomes mainstream wellness, Blueprint owns the category's most recognizable face.